Further Data Finds Lencapavir to Be Safe and Tolerable for PrEP Use
Gilead announced today that its twice-yearly injectable HIV capsid inhibitor, lenacapavir (Sunlenca), was found to be safe and tolerable for participants in a PrEP study.1 Findings from the ongoing PURPOSE 2 trial demonstrated no significant or new safety …